Introduction

B
oth use of exogenous platforms (e.g., liposomes, nanoparticles, and viral vectors) to deliver therapeutic genes and development of targeted cell therapies (e.g., modified T cells, embryonic stem cells, and induced pluripotent stem cells) have advanced from preclinical development to clinical trials and, in some cases, to standard of care for therapy. As these new therapies are developed, monitoring duration of their availability in vivo and their targeting selectivity, and correlating these parameters with treatment outcomes is critical in their evaluation and adoption for standard of care.
Incorporation of "reporter genes" which activities can be examined noninvasively by whole-body imaging provides a means to monitor both pharmacokinetics and targeting of these new vector-and cell-based therapeutic agents. In murine preclinical models, bioluminescence (e.g., alternative luciferases as reporter genes and their substrates as reporter probes) has provided convenient, inexpensive reporter genereporter probe systems to noninvasively monitor therapeutic gene delivery and cell-based therapies [1] [2] [3] [4] . However, reporter gene immunogenicity, tissue attenuation of the signal, and lack of adequate resolution preclude bioluminescence imaging in most clinical contexts. For clinical applications, the most common approach has been the use of PET reporter genes (PRGs) which activities can be monitored noninvasively by positron emission tomography (PET) [5, 6] .
Although PRGs that encode transporters, receptors, and enzymes have been developed [5, 6] , the most widely used PRG is the Herpes Simplex Virus type 1 thymidine kinase (HSV1-TK) gene. HSV1-TK can phosphorylate a variety of nucleoside analogues, including anti-herpetic acycloguanosines. HSV1-TK mutants engineered to more effectively use anti-herpetic drugs and to be less effective at phosphorylating endogenous thymidine have been developed as "suicide genes" to kill cells that ectopically express these kinases. Concurrently, positron-emitting derivatives of several acycloguanosine HSV1-TK substrates have been developed as probes for detecting HSV1-TK-based PRG expression. The combination of the HSV1-sr39TK PRG and 9- [4- 18 F-3 (hydroxymethyl) butyl]guanine ( 18 F-FHBG) as its PET reporter probe (PRP) is among the most widely used PRG/ PRP systems [6] [7] [8] [9] [10] .
Despite their current utility, immunogenicity of HSV1-TK and its derivatives limits in vivo persistence of cells expressing these PRGs, and thus their utility in clinical applications [7, 11] . Several laboratories are developing PRGs from human genes to circumvent PRG immunogenicity. Mutated versions of two human nucleoside kinases, thymidine kinase 2 (TK2) and deoxycytidine kinase (dCK), which utilize positron-emitting nucleoside analogues as PRPs have been developed in anticipation of clinical use [12] [13] [14] [15] .
As new PRG-PRP systems are described, it becomes imperative to have reliable procedures to monitor their relative specificities (the PRP should accumulate only in cells expressing the PRG) and sensitivities (the ability to generate quantifiable signals). The most common method of evaluating PRG/PRP systems has been to express PRGs in tumor cell lines, develop mouse xenografts, and image transgene PRG activity. However, differences in expression vectors (e.g., differing promoters and differing 3′ and 5′ untranslated regions), differing integration sites and copy numbers, differing rates of tumor growth, and distinctions in tumor vascularization and other biological variables make it difficult to compare such reports on relative efficacies of alternative PRP/PRG technologies.
We previously described the use of a common adenovirus delivery vector and a common gene expression construct to compare in vivo efficacy of alternative luciferase reporter genes for noninvasive imaging [16] . Postimaging measurement of hepatic viral genomes and subsequent normalization of imaging data for the hepatic reporter gene copy number eliminates any differences imposed by variations in reporter gene delivery. This assay eliminates inconsistencies due to differences in vector construction, reporter gene copy number, integration site modulation of gene expression (adenovirus genomes do not integrate into chromosomal sites), and differential vascularity of the target. Only the reporter gene and reporter probe differ in this procedure.
Our goal in establishing this procedure was to provide a common platform to evaluate reporter gene efficacy across imaging modalities. In this report, we demonstrate the utility of this procedure for evaluating differences in PRG/PRP efficacies by comparing the sensitivities of a mutated human TK2 PRG (TK2-N93D/L109F) [13] and a mutated human dCK PRG (dCK-A100V/R104M/D133A) [15, 17, McCracken et al., in preparation] to one another, using the same PRP, 2′-deoxy-2-
18 F-L-FMAU) [13] , and to the commonly used HSV1-sr39TK/ 18 F-FHBG PRG/PRP reporter system.
Materials and Methods
Adenovirus Vector Construction
Plasmids and adenoviral vectors are listed in Table 1 ; all primers are listed in Table 2 . Adenovirus vectors expressing alternative PRG were constructed as described previously [16] and in the Supplemental Material for this report. Although these reporter genes have been used, in some cases, to create adenovirus vectors previously (e.g., LUC2 and HSV1sr39TK), we have renamed the viruses created here as Ad.HL viruses to facilitate the use of these viruses as proper control and comparison viruses by other laboratories in future studies.
Adenovirus Vector Propagation and Titration
Adenovirus vectors were propagated on HEK293A cells using standard procedures [16, 17] and titrated on HeLa cells for to determine infectious genomes [16, 17] . Procedures have been described in detail in our comparisons of luciferase reporter genes [16] and are also described in the Supplemental Material.
PET Reporter Probe Synthesis
18 F-FHBG and 18 F-L-FMAU syntheses were performed as previously described [9, 13] , at the cyclotron facilities in the UCLA Crump Institute for Molecular Imaging and the UCLA Ahmanson Translational Imaging Division.
In Vivo Studies
Female hairless SKH1 mice (Charles River, San Diego, CA, USA) were housed in accordance with the UCLA Division of Laboratory Animal Medicine guidelines. Mice between 10 and 16 weeks were used for all experiments. An optimal imaging time of 3-5 days after 18 F-FHBG (200 μCi). Three hours after tracer injection, mice were anesthetized (2 % isoflurane) and subjected to microPET/CT scanning (Inveon, Siemens Medical Solutions USA Inc.; MicroCAT, Imtek Inc.) [13] . This time was chosen because it is optimal for imaging the TK2DM/ 18 F-L-FMAU PRG/PRP imaging combination in mice [13] .
To compare the efficacy of the PRG, groups of three animals were each injected via the tail vein with 5×10 10 F-L-FMAU. We did not use an ROI that covers the entire liver region because the gall bladder gives variable, nonspecific signals, both for alternative PRPs for nucleoside kinases and from mouse-to-mouse under common conditions. After imaging, the mice were euthanized, the livers were removed, and triplicate liver samples were used for adenovirus vector and mouse genomic DNA analyses. DNA was isolated from liver samples using the DNeasy protocol (Qiagen, Thousand Oaks, CA, USA), adenoviral DNA and murine genomes were determined as described previously [16, 18] , and as summarized in the Supplemental Material.
Statistical Analyses
Graph production and analysis were performed with GraphPad Prism software, version 5. Multiple group (N equal to or greater than three) comparisons were analyzed using a one-way ANOVA test. When samples were statistically significant (PG0.05) a further comparison between two sample sets were done independently using the Student's unpaired t test. Graphs displayed contain Student's t test P values.
Results
Creation and Production of Adenovirus PRG Vectors
Comparisons between reporter genes are often confounded by differences in vector structure, e.g., different promoters, alternative 5′ and/or 3′ untranslated regions, and/or distinct polyadenylation signals. We mitigated these issues by using a single vector design for all PRGs. Each reporter gene was cloned into the same shuttle or "entry" vector, utilizing the commercially available Gateway System [16] and employing PCR primers with HindIII/XhoI restriction sites. Each of these entry vectors was used to insert the reporter gene, via Gateway cloning, into the viral pAd/CMV/V5-DEST vector (Fig. 1) . This highly efficient and simple cloning procedure ensures that each adenovirus PRG vector is identical, with the exception of the reporter gene. Other researchers can easily create identical vectors, with the exception of their new reporter genes, and can evaluate their new reporter genes by direct comparison with our vectors as controls.
After conversion of the recombinant plasmid into a viral vector, amplification through serial rounds of infection, purification, and sequencing, the adenovirus vector stocks were titrated in culture for IGUs (Fig. 2) , as described in "Materials and Methods" and in the Supplemental Material. Vector concentrations, in infectious genome unit per milliliter ± SEM (Fig. 2) , were: Ad.HL.Luc2, 1.27±0.15× 
Optimal Time and Viral Titer for Imaging Hepatic PRG Expression after Intravenous Adenovirus Administration
To determine the optimal time between adenoviral reporter gene administration and injection of the reporter probe imaging agent, we performed a time course with the Ad.HL.Luc2/luciferin reporter gene/reporter probe system. Repeated daily luciferin imaging of SKH1 mice that received Ad.HL.Luc2 (5×10 10 IGU/mouse) indicated an optimal imaging window 3-5 days after adenovirus vector injection (Supplemental Material, and Supplemental Fig. 1) .
Because PRP retention is dependent on the dose of adenovirus PRG vector administration [19] (Fig. 3) . A common vector titer of 5×10 10 IGU, in the midrange of the dose-response relationship, was chosen for comparison of the various PRG/PRP systems. In this way, both greater and lesser efficacies relative to Ad.HL.sr39TK/ 18 F-FHBG for the alternative human-derived PRG/PRP systems could be evaluated.
Hepatic Efficacy of the Alternative Adenoviral PRG/PRP Noninvasive Imaging Systems
Three mice in each alternative adenoviral PRG vector experimental group and two mice in each Ad.HL.Luc2 control group were injected intravenously with the appropriate adenovirus vector (5×10 10 IGU/mouse). Four days after adenovirus injection, the mice received either 18 F-L-FMAU (200 μCi) or 18 F-FHBG (200 μCi), as appropriate. Three hours later, the mice were anesthetized and subjected to PET/CT imaging (Fig. 4a) . The following day, mice were euthanized and livers were removed. DNA was purified from liver samples, and DNA content was analyzed for viral and mouse genomes to normalize the imaging data for the number of viral genomes present in the livers. The numbers of vector genomes per liver cell, ±SEM, were Ad.HL.Luc2, 78± 2.5; Ad.HL.sr39TK, 104 ± 18; Ad.HL.TK2, 87 ± 14; Ad.HL.TK2-DM, 74±9.5; Ad.HL.dCK-WT, 43±1.5; and Ad.HL.dCK-A100VTM, 85±7.8 (Fig. 4b) .
PRG-dependent PRP hepatic retention was determined by choosing four identical 2-mm ROIs over the liver of each mouse and determining the percentage of injected dose per gram. To determine the PRG-dependent PRP retention, the Cloning and production of adenovirus vectors. Adenovirus vectors containing coding regions for TK2, TK2-DM, dCK-WT, dCK-DM, dCK-A100VTM, HSV1sr39TK (as a reference standard), and Luc2 as a negative control were constructed using Invitrogen's Gateway® Cloning System. The open reading frame of each reporter was inserted into an "entry" vector to create the pENTR-PRG plasmids and then transferred to the pAd/CMV/V5/DEST vector using the LR recombination reaction to create the seven pAd vectors. The adenoviral plasmids were linearized by PacI restriction enzyme digestion, purified, and transformed into HEK293A cells for vector rescue. After 100 % cytopathic effect was observed, lysates were serially passaged on increasing numbers of HEK293A cells with each round of infection until sufficient vector was produced, following cesium chloride buoyant density ultracentrifugation and purification for in vivo studies. Sites labeled attR1/attR2/ attL1/attL2 are the initial recombination regions; attB1/attB2 are the recombination regions after the LR recombination reaction. Cm R chloramphenicol resistance gene, Km R kanamycin resistance gene, Ap R ampicillin resistance gene, ccdB the coding region for the cytotoxic protein CcdB used as a negativeselection marker in recombined clones, P CMV CMV promoter, TKpA thymidine kinase polyadenylation signal, 5′ ITR the viral 5′-inverted terminal repeats, wt Ad5 (DE3) Ad5 sequences that include a 3′ ITR and packaging signal. To eliminate the variability caused by differences in the number of PRGs present in the liver of each mouse, the [%ID/ g-bkg] was normalized to vector transduction. Results for the alternative PRG vectors were then compared to the Ad.HL.sr39TK/ 18 F-FHBG standard. Normalized activities (Fig. 4d) were Ad.HL.sr39TK, 100±19 %; Ad.HL.TK2, 5.0±1.2 %; Ad.HL.TK2-DM, 107±32 %; Ad.HL.dCK-WT, 5.0±0.6 %; and Ad.HL.dCK-A100VTM, 197±23 %. Normalized PRG/PRP signal showed no significant difference between the commonly used HSV1sr39TK/ 18 F-FHBG PRG/ PRP imaging system and the mutant human thymidine kinase 2 (TK2-DM)/ 18 F-L-FMAU imaging system by Student's t test (p00.86) In contrast, a significant (p00.03) difference between the HSV1sr39TK/ 18 F-FHBG and mutant human deoxycytidine kinase (dCK-A100VTM)/ 18 F-L-FMAU PRG/PRP combinations was observed. Although a difference in the TK2-DM/ 18 F-L-FMAU and dCK-A100VTM/ 18 F-L-FMAU imaging systems did not reach significance (p00.08), there appears to be a trend in that direction.
We also compared the efficacy of the dCK-DM reporter gene described by Likar et al. [13] with the dCK-A100VTM reporter gene, which has an additional amino acid substitution that was speculated to improve its utility as a PRG [20] , using Ad.HL.dCK-DM and Ad.HL.dCKA100VTM adenovirus vectors. However, in this assay, we could not observe a statistically significant difference in the efficacy of dCK-DM and dCK-A100VTM using 18 F-L-FMAU as a common PRP (described in the Supplemental Materials and Supplemental Fig. 2) .
Discussion
As the use of therapeutic gene delivery vectors and targeted cell therapies expands into clinical applications, the need to repeatedly, noninvasively, and quantitatively monitor the duration of their bioavailability, the specificity of their targeting, and their longevity at target sites becomes of increasingly greater importance in evaluating their relative therapeutic efficacies. As new reporter gene/reporter probe imaging systems are developed, a robust, quantifiable means for their evaluation becomes essential. The procedure we developed eliminates all variables except the reporter gene and the reporter probe, restricting comparisons to a single, similarly vascularized organ and permitting postimaging normalization for the number of reporter genomes [16] .
HSV1-TK and its mutated derivatives have become the de facto "gold standard" PRGs for PRG/PRP analysis in "translational" preclinical models and in clinical trials. However, because of the immunogenicity of HSV1-TK and its derivatives, several groups have developed mutated human nucleoside kinases as PRGs. The "ideal" mutated nucleoside kinase PRG would (1) not be immunogenic in patients, (2) use as its PRP substrate a positron-emitting nucleoside analogue unable to be phosphorylated by the endogenous enzyme, and (3) be unable to phosphorylate the endogenous substrate.
To date, several mutant human nucleoside kinase PRG/ PRP noninvasive imaging systems have been described. Two PRG studies have been published utilizing 2′-deoxy-2-18 F-5-methyl-1-β-L-arabinofuranosyluracil ( 18 F-FEAU) as the PRP; the first used a truncated human TK2 gene as a PRG [21] , while the second used a human dCK double mutant (dCK-R104M/D133A) [12] . More recently, two additional studies have used 18 F-FMAU as a PRP; one of these studies used a TK2 double mutant as the PRP [13] and the second used a dCK triple mutant (dCK-A100VTM) [McCracken et al., in preparation] .
To begin the comparison of alternative PRG/PRP imaging combinations, using the rigorous system developed previously [16] , we compared the efficacies of the TK2-DM and dCK-A100VTM PRGs, using the common PRP 18 F-L-FMAU, to the efficacy of the HSV1sr39TK/ 18 F-FHBG PRG/PRP imaging combination. Our data suggest that in the adenovirus/hepatic mouse model system we developed, the TK2-DM/ 18 F-L-FMAU PRG/PRP combination is as effective as the HSV1sr39TK/ 18 F-FHBG combination, while the dCK-A100VTM/ 18 F-L-FMAU PRG/PRP combination has a significant advantage over the HSV1sr39TK/ 18 F-FHBG combination (Fig. 4) .
As we developed this comparative analytical system for PRG/PRP imaging combinations, it became apparent that there are a number of additional constraints, considerations, and pitfalls to take into account in comparing alternative PRG/PRP systems. We compared two reporter genes (TK2-DM and dCK-A100VTM) both to one another, using a common PRP ( 18 F-L-FMAU), and to a distinct PRG/PRP imaging system (HSV1sr39TK/ 18 F-FHBG). While all three PRGs are expressed from the same expression vector and the transgene PRG copy numbers can be determined after imaging, thus assuring that the imaging results can be normalized for levels of PRG expression, we do not know if the two 18 F-PRPs are present in adequate levels in the liver for comparable use as substrates. While the efficacy comparisons of TK2-DM/ 18 F-L-FMAU and dCK-A100VTM/ 18 F-L-FMAU in the liver are controlled for essentially all variables, it is quite possible that the relative availabilities of the 18 F-FHBG and 18 F-L-FMAU PRP substrates may be quite different in the liver for these alternative PRGs. Thus, substrate availability, and not PRG expression, may be limiting, perhaps in a tissue-specific fashion, for PRP/PRG reporter systems. In preclinical reporter gene/reporter probe systems, this is perhaps most graphically illustrated by the firefly luciferase/luciferin system; no matter what the level of luciferase expression, no image can be detected in the brain-luciferin cannot penetrate the bloodbrain barrier.
A second pitfall for translation from preclinical to clinical applicability for PRG/PRP imaging systems in patients lies in differences between mice (and other species used in preclinical analyses) and humans for PRP biodistribution. 18 F-L-FMAU biodistribution in mice, using a xenograft tumor model, showed no significant probe retention in tissues other than tumor, with variable signal in intestine. Indeed, in mice, the nonspecific probe retention for 18 F-L-FMAU was less than that observed for 18 F-FHBG [13, 22] . However, in distribution studies in humans, extensive hepatic 18 F-L-FMAU retention was observed [13] , suggesting that the clinical use of either the TK2-DM/ 18 F-L-FMAU PRG/PRP reporter system or the dCK-A100VTM/ 18 F-L-FMAU PRG/PRP monitoring system in patients will be restricted to extrahepatic applications.
In [12] of their dCK-based PRG with those of the TK2-based PRG by Campbell et al. [13] ; these reports used different vectors, different transduced tumor cells, different xenograft conditions likely to lead to distinct target sizes and variable vascularization, and distinct PRPs. Using a rigorous protocol that equalizes many of these conditions in preclinical studies will help to make the pursuit of clinically useful systems more effective. For example, by comparing alternative substrates (e.g., 18 F-FEAU and 18 F-L-FMAU) in this adenovirus-based model and evaluating the biodistribution of the two PRPs, a definitive comparison of the two presumably nonimmunogenic PRGs (TK2-DM and dCK-A100VTM) and the two alternative PRPs (  18 F-FEAU and   18 F-L-FMAU) could be performed. Differences in biodistribution for potential PRPs between mouse and human, or between human and any other species, presents an often unanticipated but significant barrier in PRP/PRG imaging system development. 18 F-L-FMAU is a case in point; its pristine lack of retention in mice is, unfortunately, not reflected in human studies [13] . As a result, we are adopting a new "reverse" approach to the development of PRG/PRP imaging systems. Alternative positron-emitting nucleoside analogues are synthesized, and biodistribution studies are carried out in volunteers to identify potential PRPs with optimal biodistribution characteristics [23] . After identification of potential PRPs with appropriate biodistribution properties, modifications of nucleoside kinases are made and in vitro analyses of their ability to phosphorylate both the modified and the endogenous substrates are evaluated to identify mutant PRGs that can phosphorylate the potential PRP and have reduced kinase activity on the endogenous substrate.
Reducing the ability of the mutated nucleotide kinase PRG to utilize the endogenous substrate may appear to be simply a bonus because it will effectively increase the specific activity in vivo of the PRG for the PRP; the "cold" endogenously produced compound will no longer compete with the positron-emitting PRP for the mutated PRG nucleotide kinase. However, there is another important potential value in reducing/eliminating PRG kinase activity for the endogenous substrate. While the PRPs are present in tracer, nonphysiological amounts and will have no biological effect, high PRG levels, if active on an endogenous substrate, might drastically modify nucleoside/nucleotide pools in target cells and, as a result, have profound biological consequences. In principle, the "ideal" PRG kinase would be orthogonal to the native enzyme, able to phosphorylate the positron-emitting PRP and unable to phosphorylate the endogenous substrate (or any other cellular component).
It is clear that reporter probe biodistribution, duration of availability, and clearance from tissues will present problems that must be overcome in optimizing noninvasive reporter gene/reporter probe combinations. Similarly, optimizing reporter gene delivery, bioavailability, and expression are among the many factors that must also be considered in developing optimal clinical reporter gene/reporter probe combinations for patient applications, whether the analysis be PET, SPECT, MRI, ultrasound, etc. We anticipate that using rigorously controlled experimental methodologies, like the one used here, will be required to bring the best methods for reporter gene/reporter probe imaging to the clinic as rapidly and cost-effectively as possible.
